.Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CH03_Tasimelteon.Tasimelteon .Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CH03_Tasimelteon.Tasimelteon| name: | Tasimelteon | |
| ATC code: | N05CH03 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 92 | L |
| clearance: | 16.4 | L/h |
| other parameters in model implementation | ||
Tasimelteon is a melatonin receptor agonist targeting MT1 and MT2 receptors, approved for the treatment of non-24-hour sleep-wake disorder (Non-24), primarily in totally blind adults. It is also investigated for circadian rhythm sleep disorders. The drug is currently approved and in use.
Healthy adult volunteers; oral administration; single and repeated doses.